Abstract
Schizophrenia is associated with high prevalence of substance abuse. Recent research suggests that dysregulation of N-methyl-d-aspartate receptor (NMDAR) function may play a role in the pathophysiology of both schizophrenia and drug addiction, and thus, may account for this high comorbidity. Our laboratory has developed two transgenic mouse lines that exhibit contrasting NMDAR activity based on the availability of the glycine modulatory site (GMS) agonists d-serine and glycine. Glycine transporter 1 knockdowns (GlyT1+/−) exhibit NMDAR hyperfunction, whereas serine racemase knockouts (SR−/−) exhibit NMDAR hypofunction. We characterized the behavior of these lines in a cocaine-induced (20 mg/kg) conditioned place preference (CPP) and locomotor sensitization paradigm. Compared with wild-type mice, GlyT1+/− mice displayed hastened extinction of CPP and robust cocaine-induced reinstatement. SR−/− mice appeared to immediately “forget” the learned preference, because they did not exhibit cocaine-induced reinstatement and also displayed attenuated locomotor sensitization. Treatment of GlyT1+/− mice with gavestinel (10 mg/kg on day 1; 5 mg/kg on days 2–17), a GMS antagonist, attenuated cocaine-induced CPP and caused them to immediately “forget” the learned preference. Treatment of SR−/− mice with d-serine (300 mg/kg on day 1; 150 mg/kg on days 2–17) to normalize brain levels caused them to avoid the cocaine-paired side of the chamber during extinction. These results highlight NMDAR dysfunction as a possible neural mechanism underlying comorbid schizophrenia and substance abuse. Also, these findings suggest drugs that directly or indirectly activate the NMDAR GMS could be an effective treatment of cocaine abuse.
Footnotes
- Received January 20, 2015.
- Accepted March 9, 2015.
This work was supported by National Institutes of Health National Institute on Drug Abuse [Grant T32-DA015036]; and the National Institutes of Health National Institute of Mental Health [Grant R01-MH51290].
- Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|